Brief: Nasdaq Approves Biosergen's Delisting Application
17/09/2026 15:32
BRIEF-Nasdaq Approves Biosergen's Delisting Application Sept 17 (Reuters) - Biosergen AB BIOSGN.ST:
NASDAQ APPROVES BIOSERGEN'S APPLICATION FOR DELISTING FROM FIRST NORTH GROWTH MARKET
DELISTING CONDITIONAL UPON SWEDISH COMPANIES REGISTRATION OFFICE GRANTING PERMISSION TO EXECUTE MERGER WITH FLERIE
LAST DAY OF TRADING IN COMPANY'S SHARES ON NASDAQ FIRST NORTH GROWTH MARKET IS EXPECTED TO BE OCTOBER 21, 2026
Source text: ID:nWkr6hRhbk
Further company coverage: BIOSGN.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Flerie AB
See all newsBrief: Flerie Q3 Net Asset Value SEK 3,113 Million
Brief: Flerie Portfolio Co Reports Positive Data From Clinical Proof-Of-Mechanism Study
Brief: Flerie Writes Down Value Of Holding In Empros Pharma
Brief: Nasdaq Approves Biosergen's Delisting Application
Brief: Flerie Approves Merger Plan For Flerie And Biosergen